Shanghai Pharmaceuticals Holding Co Ltd
SSE:601607
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Balmer Lawrie and Company Ltd
NSE:BALMLAWRIE
|
IN |
|
5
|
5I5j Holding Group Co Ltd
SZSE:000560
|
CN |
Shanghai Pharmaceuticals Holding Co Ltd
Capital Expenditures
Shanghai Pharmaceuticals Holding Co Ltd
Capital Expenditures Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Capital Expenditures | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
Shanghai Pharmaceuticals Holding Co Ltd
SSE:601607
|
Capital Expenditures
-¥2.2B
|
CAGR 3-Years
20%
|
CAGR 5-Years
8%
|
CAGR 10-Years
-3%
|
|
|
Sinopharm Group Co Ltd
HKEX:1099
|
Capital Expenditures
-¥1.3B
|
CAGR 3-Years
17%
|
CAGR 5-Years
11%
|
CAGR 10-Years
3%
|
|
|
Jointown Pharmaceutical Group Co Ltd
SSE:600998
|
Capital Expenditures
-¥1.4B
|
CAGR 3-Years
-3%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
-4%
|
|
|
C
|
China National Medicines Corp Ltd
SSE:600511
|
Capital Expenditures
-¥70.6m
|
CAGR 3-Years
17%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
6%
|
|
|
Huadong Medicine Co Ltd
SZSE:000963
|
Capital Expenditures
-¥1.9B
|
CAGR 3-Years
-19%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
-24%
|
|
|
C
|
China National Accord Medicines Corp Ltd
SZSE:000028
|
Capital Expenditures
-¥252.5m
|
CAGR 3-Years
11%
|
CAGR 5-Years
2%
|
CAGR 10-Years
0%
|
|
Shanghai Pharmaceuticals Holding Co Ltd
Glance View
Shanghai Pharmaceuticals Holding Co Ltd, a giant in China's pharmaceutical industry, operates with a dual-engine strategy that seamlessly combines manufacturing and distribution. Established in the bustling metropolis of Shanghai, the company has swiftly become a cornerstone of China's healthcare landscape. Its manufacturing arm is a powerhouse of innovation and production, turning out a vast array of pharmaceutical products that encompass both traditional Chinese medicine and modern pharmaceuticals. These products range from patented medicines to essential generics, entering hospitals, clinics, and retail pharmacies nationwide, all the while feeding a robust supply chain that caters to the country's vast and diverse market needs. On the flip side, Shanghai Pharmaceuticals' extensive distribution network is the lifeline that ensures these vital medicines reach their destinations safely and efficiently. In an era where logistics and supply chain management are pivotal, the company excels through an advanced distribution system that connects manufacturers with end-users across China. This network is bolstered by strategic partnerships and a commitment to technological advancement, allowing the company to maintain agility and reliability in an ever-evolving market. Revenue streams flow not just from product sales but are heavily supplemented through strategic partnerships and services that enhance accessibility and affordability for healthcare providers and patients alike. As one of the top pharmaceutical firms in China, Shanghai Pharmaceuticals is adept at maneuvering the intricacies of healthcare demands, regulatory landscapes, and competitive dynamics, carving its niche as a leader in both innovation and distribution efficiency.
See Also
What is Shanghai Pharmaceuticals Holding Co Ltd's Capital Expenditures?
Capital Expenditures
-2.2B
CNY
Based on the financial report for Sep 30, 2025, Shanghai Pharmaceuticals Holding Co Ltd's Capital Expenditures amounts to -2.2B CNY.
What is Shanghai Pharmaceuticals Holding Co Ltd's Capital Expenditures growth rate?
Capital Expenditures CAGR 10Y
-3%
Over the last year, the Capital Expenditures growth was 14%. The average annual Capital Expenditures growth rates for Shanghai Pharmaceuticals Holding Co Ltd have been 20% over the past three years , 8% over the past five years , and -3% over the past ten years .